CAR T-Cell Therapy for CLL: A New Addition to Our Treatment Toolbox?

Abstract: Treatment of high-risk chronic lymphocytic leukemia (CLL) has undergone a revolution in recent years with the introduction of novel agents. Bruton kinase inhibitors (BTK) inhibitors, […]

Chimeric Antigen Receptor Natural Killer Cells for the Treatment of Patients With B-Cell Malignancies

H&O What are the outcomes associated with chimeric antigen receptor (CAR) T-cell therapy in patients with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL)? KR […]

Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic

H&O What are the goals of the CAR T-Cell Consortium? MB The initial aim of the CAR T-Cell Consortium was to evaluate real-world experience with […]

Advances in CAR T-Cell Therapy for the Treatment of Multiple Myeloma

H&O What is the rationale for the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma? NS Multiple myeloma cells express B-cell maturation […]

Highlights in CAR T-Cell Therapy From the 61st American Society of Hematology Annual Meeting

A Review of Selected Presentations From the 61st ASH Meeting • December 7-10, 2019 • Orlando, Florida CD19-Loss With Preservation of Other B-Cell Lineage Features […]

CAR T-Cell Therapy Against B-Cell Maturation Antigen in Multiple Myeloma

H&O Could you please describe B-cell maturation antigen? AC B-cell maturation antigen (BCMA) is a cell-surface receptor that is expressed primarily by plasma cells, including […]

Advances in CAR T-Cell Therapy for Chronic Lymphocytic Leukemia

H&O How does CAR T-cell therapy work? DP A patient’s T cells are removed through leukapheresis and then genetically modified in the laboratory so that […]